Semaglutide 2.4 mg reduced total cardiovascular events by 22% in people with established cardiovascular disease (CVD) and overweight or obesity without diabetes.1 Obesity directly leads to cardiovascular morbidity, mortality and… Read More
Building on results of the landmark SELECT trial, SCORE shows cardiovascular (CV) risk reduction with use of semaglutide 2.4 mg in a real-world environment1 SCORE is a retrospective, observational analysis… Read More
VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement – Zimislecel… Read More
BC led research to transform early disease detection, treatment and health equity using cutting edge genomic technologies. VANCOUVER, BC — Genome BC has helped secure more than $49 million for… Read More
X-platform bioreactors are designed to help navigate challenges by combining reliability, scalability, and flexibility in one solution Scientists and researchers can seamlessly scale from 50L to 2 000L to meet… Read More
